Arpita Gandhi, MD
Hematology · Portland, ORNPI 1225329246
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $802 of the $1,094 with a category attached, or 73.3%. National Marrow Donor Program accounts for 87.6% of it on its own, with 2 other manufacturers making up the rest.
Across 6 payments — averaging $182.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- National Marrow Donor Program$958
- Jazz Pharmaceuticals Inc.$106
- Novartis$30
Across 6 payments — averaging $17,151 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$55K
- National Marrow Donor Program$33K
- Syndax Pharmaceuticals, Inc.$15K
- Incyte Corporation$236
What the payments were for
- Travel & lodging$80273%
- Food & beverage$29227%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| National Marrow Donor Program | 4 | $958 |
| Jazz Pharmaceuticals Inc. | 1 | $106 |
| Novartis | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEFITELIO$106
How this compares
$1,094 in reported general payments places this provider in the 55th percentile of 27 hematology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 70 | $1,092,547 |
| RezurockBelumosudil Mesylate | 15 | $434,465 |
| Posaconazole | 20 | $14,182 |
| Voriconazole | 12 | $7,217 |
| Cefpodoxime Proxetil | 11 | $3,363 |
| Acyclovir | 100 | $1,388 |
| GengrafCyclosporine, Modified | 18 | $1,041 |
| Tacrolimus | 11 | $572 |
| Penicillin V Potassium | 39 | $355 |
| Omeprazole | 29 | $308 |
| Carvedilol | 30 | $246 |
| Celecoxib | 13 | $216 |
| Famotidine | 26 | $194 |
| Levofloxacin | 14 | $188 |
| Prednisone | 19 | $180 |
Paid to pharmacies, not to this prescriber.
Other hematology in Portland
- John GodwinPortland$52K
- Rebecca SilbermannPortland$26K
- Jessica LeonardPortland$26K
- Ronan SwordsPortland$11K
- Andy ChenPortland$11K
- Hugo AkabanePortland$11K
- Guang FanPortland$7K
- Rachel CookPortland$7K
- Anusha VallurupalliPortland$5K
- Elizabeth MillerPortland$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.